

IDS Form PTO/SB/08: Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	10/571,991
				Filing Date	March 15, 2006
				First Named Inventor	Hennequin
				Art Unit	1624
				Examiner Name	Douglas M. WILLIS
Sheet	1	of	2	Attorney Docket Number	09963.0008-00000

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initials	Cite No.	Document Number Number-Kind Code (if known)	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation
	1	<i>In re Hilmer</i> , 359 F.2d 859, 149 USPQ 480 (CCPA 1966)	
	2	<i>In re Deckler</i> , 977 F.2d 1449, 24 USPQ2d 1448 (Fed. Cir. 1992)	
	3	<i>Ex parte Tytgat</i> , 225 USPQ 907 (Bd. Pat. App. & Inter. 1985)	
	4	37 CFR §41.127(a)(1)	
	5	<i>Ex parte Kimura</i> , 55 USPQ2d 1537 (Bd. Pat. App. & Inter. 2000)	
	6	<i>Ex parte A</i> , 17 USPQ2d 1716 (Bd. Pat. App. & Inter. 1990)	
	7	<i>Net Money!N, Inc. v. Verisign, Inc.</i> , 545 F.3d 1359 (Fed. Cir. 2008)	
	8	<i>Eisai Co. Ltd. v. Teva Pharmaceuticals USA, Inc.</i> , 533 F.3d 1353 (Fed. Cir. 2008)	
	9	<i>In re Baird</i> , 16 F.3d 380, 382, 29 USPQ2d 1550 (Fed. Cir. 1994)	
	10	<i>In re Jones</i> , 958 F.2d 347 (Fed. Cir. 1992)	
	11	<i>Takeda Chemical Industries, Ltd. V. Alphapharm Pty., Ltd.</i> , 492 F.3d 1350 (Fed. Cir. 2007)	
	12	<i>In re Deuel</i> , 51 F.3d 1552 (Fed. Cir. 1995)	
	13	Pages from Federal Register's Notice of Proposed Rulemaking, 49 FR 3768, dated January 30, 1984	
	14	<i>Tafas v. Doll</i> , slip op. (Fed. Cir. March 20, 2009)	
	15	<i>In re Wilding</i> , 535 F.2d 631 (1976, CCPA)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	2	of	2
-------	---	----	---

**Complete if Known**

<b>Application Number</b>	10/571,991
<b>Filing Date</b>	March 15, 2006
<b>First Named Inventor</b>	Hennequin
<b>Art Unit</b>	1624
<b>Examiner Name</b>	Douglas M. WILLIS
<b>Attorney Docket Number</b>	09963.0008-00000

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation
-------------------	----------	---	-------------

16	<i>In re Kaplan</i> , 789 F.2d 1574 (Fed. Cir. 1986)
----	--

17	<i>In re Sarrett</i> , 327 F.2d 1005, (CGPA 1964)
----	---

<sup>18</sup> *The Procter & Gamble Company v. Teva Pharmaceuticals USA, Inc.*, \_\_\_ F.3d \_\_\_, No. 2008-1404, -1405, -1406 (Fed. Cir. May 13, 2009)

<sup>19</sup> *In re Kubin*, \_\_ F.3d \_\_, No. 2008-1184, (Fed. Cir. Apr. 3, 2009)

Examiner  
SignatureDate  
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.